'''Raloxifene''' (marketed as '''Evista''' by [[Eli Lilly and Company]]) is an oral [[selective estrogen receptor modulator]] (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast.<ref>{{cite journal |author1=Muchmore DB | title = Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects. | journal = The oncologist | volume = 5 | issue = 5 | pages = 388â€“392 | year = 2000 | url = http://theoncologist.alphamedpress.org/content/5/5/388.long | pmid = 11040275| doi = 10.1634/theoncologist.5-5-388}}</ref> It is used in the prevention of [[osteoporosis]] in postmenopausal women and to reduce the risk of invasive [[breast cancer]] in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.<ref>{{cite press release |title=FDA Approves New Uses for Evista 

 
A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen and raloxifene, used to treat breast cancer, significantly reduce invasive breast cancer in midlife and older women, but also increase the risk of adverse side effects.<ref>{{cite web| url=http://archive.ahrq.gov/news/newsroom/press-releases/2009/brcanmed.html | title=Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects | author=Agency for Healthcare Research and Quality, Rockville, MD.| accessdate=2009-09-14|date=September 2009}}</ref>
